Neurodegenerative Diseases

Papers
(The TQCC of Neurodegenerative Diseases is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline20
Inflammatory Cytokine Levels in Patients with Sporadic Amyotrophic Lateral Sclerosis16
Association between Gut Microbiota with Mild Cognitive Impairment and Alzheimer’s Disease in a Thai Population14
Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity12
Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson’s Disease and Atypical Parkinsonian Syndromes9
Prevalence of Gastrointestinal Symptoms, Severity of Dysphagia, and Their Correlation with Severity of Amyotrophic Lateral Sclerosis in a Mexican Cohort9
The Immunomodulatory Potential Role of Mesenchymal Stem Cells in Diseases of the Central Nervous System8
Homoharringtonine Inhibits Alzheimer’s Disease Progression by Reducing Neuroinflammation via STAT3 Signaling in APP/PS1 Mice6
Heart Rate Variability during Wake and Sleep in Huntington’s Disease Patients: An Observational, Cross-Sectional, Cohort Study5
Synaptic Neurofilaments and GluN1-Neurofilament Light Chain Interaction in Experimental Models of α-Synucleinopathies5
Neuroprotective and Therapeutic Effects of Tocovid and Twendee-X on Aβ Oligomer-Induced Damage in the SH-SY5Y Cell Line4
Early Autonomic Symptoms Predict Functional Decline in Parkinson’s Disease Independent of Dopaminergic Therapy3
Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson’s Disease3
Heart Rate Variability in Huntington Disease: A Long-Term Longitudinal Study3
Sexuality and Neurodegenerative Disease: An Unmet Challenge for Patients, Caregivers, and Treatment3
0.015223979949951